Cargando…
Serum and Lung Pharmacokinetics of ASN100, a Monoclonal Antibody Combination for the Prevention and Treatment of Staphylococcus aureus Pneumonia
BACKGROUND: Monoclonal antibodies (mAbs) are well-suited for the prevention and treatment of acute bacterial infections. ASN100 is a combination of two fully human IgG1 mAbs, ASN-1 and ASN-2 that together neutralize six Staphylococcus aureus cytotoxins, alpha-hemolysin (Hla) and five leukocidins (Hl...
Autores principales: | Magyarics, Zoltan, Leslie, Fraser, Luperchio, Steven A, Bartko, Johann, Schörgenhofer, Christian, Schwameis, Michael, Derhaschnig, Ulla, Lagler, Heimo, Stiebellehner, Leopold, Jilma, Bernd, Stevens, Christopher, Nagy, Eszter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631769/ http://dx.doi.org/10.1093/ofid/ofx163.722 |
Ejemplares similares
-
Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting Staphylococcus aureus Cytotoxins in the Lung Epithelial Lining Fluid of Healthy Volunteers
por: Magyarics, Zoltan, et al.
Publicado: (2019) -
Dissociation between systemic and pulmonary anti‐inflammatory effects of dexamethasone in humans
por: Bartko, Johann, et al.
Publicado: (2016) -
1408. Population Pharmacokinetic (PK) Model to Describe Epithelial Lining Fluid (ELF) Penetration of ASN-1 and ASN-2 after ASN100 Administration to Healthy Subjects
por: Van Wart, Scott A, et al.
Publicado: (2018) -
Dexamethasone inhibits endotoxin‐induced coagulopathy in human lungs
por: Bartko, J., et al.
Publicado: (2016) -
Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing
por: Schoergenhofer, Christian, et al.
Publicado: (2018)